Related Experiment Video

Updated: Aug 30, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias

C S Chim1, A S Y Wong, Y L Kwong

  • 1University Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.

Annals of Hematology
|September 27, 2003
PubMed

Insights

Gene promoter hypermethylation inactivates the INK4/CDK/RB pathway in leukemia, primarily affecting p15 and p16. This methylation was linked to AML M2 subtype but did not impact patient survival or remission rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cell cycle dysregulation is a key factor in cancer development.
  • The INK4 family CKI/CDK/RB pathway plays a critical role in cell cycle control and is frequently altered in oncogenesis.
  • Gene promoter hypermethylation is a significant mechanism for gene silencing in cancer.

Purpose of the Study:

  • To investigate the role of gene promoter hypermethylation in the inactivation of the INK4 family CKI/CDK/RB pathway during leukemogenesis.
  • To determine the frequency of p15, p16, p18, and RB gene promoter methylation in leukemia cell lines and patient samples.
  • To assess the association of p15 and p16 methylation with specific leukemia subtypes and clinical outcomes.

Main Methods:

  • Methylation-specific polymerase chain reaction (MSP) was employed using primers for methylated (M-MSP) and unmethylated (U-MSP) alleles.
  • The study analyzed five leukemia cell lines, 50 acute myeloid leukemia (AML) samples, and 25 acute lymphoblastic leukemia (ALL) samples.
  • Clinical data, including complete remission (CR), overall survival (OS), and disease-free survival (DFS), were correlated with methylation status.

Main Results:

  • p15 methylation was observed in 58% of AML and 40% of ALL patients, while p16 methylation occurred in 4% of AML and 8% of ALL patients.
  • p15 methylation in AML was significantly associated with the M2 subtype (p=0.018).
  • No methylation of p18 or RB genes was detected in cell lines or patient samples. Concurrent p15 and p16 methylation was rare.

Conclusions:

  • Methylation-driven inactivation of the INK4/CDK/RB pathway in leukemia primarily involves the p15 gene and occasionally the p16 gene.
  • p15 gene methylation is associated with the M2 subtype of AML.
  • p15 methylation did not serve as a prognostic marker for CR, OS, or DFS in the studied leukemia patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.